ERBB2 and triple-negative breast carcinoma: pPR was reported in 20 (45.5%) HER2+/HR+ patients, in 7 (22.6%) HER2+/HR-negative patients, in 48 (75.8%) HER2-negative/HR+ patients and in 13 (44.8%) triple negative breast cancer patients.